CTKB - Company ID 0001831915
The table below shows Cytek Biosciences, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $44.13M | $52.29M | $45.60M | $41.46M | $51.50M | $46.62M |
| Cost of revenue | $22.88M | $24.74M | $21.73M | $21.30M | $22.50M | $21.18M |
| Gross profit | $21.25M | $27.55M | $23.87M | $20.16M | $29.00M | $25.44M |
| R&D | $9.60M | $8.96M | $8.83M | $9.72M | $9.88M | $10.00M |
Cytek Biosciences, Inc. reported annual revenue of $201.49M for fiscal year 2025. That is up 0.5% from $200.45M in fiscal 2024. Over the 6 fiscal years shown, annual revenue grew from $710.00K (FY 2020) to $201.49M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A | $18.47M | $16.12M | $13.53M | $12.90M | $10.94M | $11.69M |
| Operating income | -$18.46M | -$9.19M | -$10.62M | -$14.97M | -$4.25M | -$8.53M |
| Income tax | $1.49M | -$2.29M | -$1.19M | $136.00K | -$784.00K | $3.25M |
| Net income | -$18.87M | - | - | -$11.40M | - | - |
| EPS (diluted) | - | - | - | - | - | - |